Cargando…

A stress-responsive enhancer induces dynamic drug resistance in acute myeloid leukemia

The drug efflux pump ABCB1 is a key driver of chemoresistance, and high expression predicts treatment failure in acute myeloid leukemia (AML). In this study, we identified and functionally validated the network of enhancers that controls expression of ABCB1. We show that exposure of leukemia cells t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Williams, Mark S., Amaral, Fabio M.R., Simeoni, Fabrizio, Somervaille, Tim C.P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7269587/ https://www.ncbi.nlm.nih.gov/pubmed/31770110 http://dx.doi.org/10.1172/JCI130809

Ejemplares similares

Dynamic induction of drug resistance through a stress-responsive enhancer in acute myeloid leukemia
por: Williams, Mark S., et al.
Publicado: (2020)

Differentiation block in acute myeloid leukemia regulated by intronic sequences of FTO
por: Camera, Francesco, et al.
Publicado: (2023)

Enhancer recruitment of transcription repressors RUNX1 and TLE3 by mis-expressed FOXC1 blocks differentiation in acute myeloid leukemia
por: Simeoni, Fabrizio, et al.
Publicado: (2021)

Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity
por: Williams, Mark S., et al.
Publicado: (2021)

Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia
por: Maiques-Diaz, Alba, et al.
Publicado: (2018)

Emerging Epigenetic Therapeutic Targets in Acute Myeloid Leukemia
por: Wingelhofer, Bettina, et al.
Publicado: (2019)

Derepression of the Iroquois Homeodomain Transcription Factor Gene IRX3 Confers Differentiation Block in Acute Leukemia
por: Somerville, Tim D.D., et al.
Publicado: (2018)

Mechanisms of drug resistance in acute myeloid leukemia
por: Zhang, Jing, et al.
Publicado: (2019)

TTC5 is required to prevent apoptosis of acute myeloid leukemia stem cells
por: Lynch, J T, et al.
Publicado: (2013)

Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem Cells
por: Niu, Jialan, et al.
Publicado: (2022)

HMG20B stabilizes association of LSD1 with GFI1 on chromatin to confer transcription repression and leukemia cell differentiation block
por: Maiques-Diaz, Alba, et al.
Publicado: (2022)

Frequent reconstitution of IDH2(R140Q) mutant clonal multilineage hematopoiesis following chemotherapy for acute myeloid leukemia
por: Wiseman, Daniel H., et al.
Publicado: (2016)

LSD1: biologic roles and therapeutic targeting
por: Maiques-Diaz, Alba, et al.
Publicado: (2016)

Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia
por: Deb, Gauri, et al.
Publicado: (2019)

TP-0903 is active in models of drug-resistant acute myeloid leukemia
por: Jeon, Jae Yoon, et al.
Publicado: (2020)

A novel approach to overcome drug resistance in acute myeloid leukemia
por: Mazewski, Candice, et al.
Publicado: (2023)

A targeted knockdown screen of genes coding for phosphoinositide modulators identifies PIP4K2A as required for acute myeloid leukemia cell proliferation and survival
por: Jude, Julian G, et al.
Publicado: (2014)

Loss of KDM6A confers drug resistance in acute myeloid leukemia
por: Stief, Sophie M., et al.
Publicado: (2019)

Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia
por: Gebru, Melat T., et al.
Publicado: (2020)

Suppressing Hedgehog signaling reverses drug resistance of refractory acute myeloid leukemia
por: Huang, Kaikai, et al.
Publicado: (2019)

A Role for the Bone Marrow Microenvironment in Drug Resistance of Acute Myeloid Leukemia
por: Bolandi, Seyed Mohammadreza, et al.
Publicado: (2021)

Drug Repurposing for the Treatment of Acute Myeloid Leukemia
por: Andresen, Vibeke, et al.
Publicado: (2017)

Immunomodulatory Drugs in Acute Myeloid Leukemia Treatment
por: Piccolomo, Antonio, et al.
Publicado: (2020)

Recent drug approvals for acute myeloid leukemia
por: Lai, Catherine, et al.
Publicado: (2019)

A mechanism for increased sensitivity of acute myeloid leukemia to mitotoxic drugs
por: Panina, Svetlana B., et al.
Publicado: (2019)

Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia
por: Gurnari, Carmelo, et al.
Publicado: (2020)

Resistance to targeted therapies in acute myeloid leukemia
por: Mecklenbrauck, Rabea, et al.
Publicado: (2022)

Enhancers of Polycomb EPC1 and EPC2 sustain the oncogenic potential of MLL leukemia stem cells
por: Huang, Xu, et al.
Publicado: (2013)

Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia)
por: Lin, Min, et al.
Publicado: (2018)

A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia
por: Korfi, K., et al.
Publicado: (2015)

CD9, a potential leukemia stem cell marker, regulates drug resistance and leukemia development in acute myeloid leukemia
por: Liu, Yongliang, et al.
Publicado: (2021)

Deregulation of Mitochondrial ATPsyn-β in Acute Myeloid Leukemia Cells and with Increased Drug Resistance
por: Xiao, Xiang, et al.
Publicado: (2013)

Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML)
por: Mohamed, Aminetou Mint, et al.
Publicado: (2015)

Combination of coumarin and doxorubicin induces drug-resistant acute myeloid leukemia cell death
por: Al-Abbas, Nouf S., et al.
Publicado: (2021)

Properties of Leukemic Stem Cells in Regulating Drug Resistance in Acute and Chronic Myeloid Leukemias
por: Zhai, Xingjian, et al.
Publicado: (2022)

Clonal Architecture and Evolutionary Dynamics in Acute Myeloid Leukemias
por: Duchmann, Matthieu, et al.
Publicado: (2021)

Time for Dynamic Assessment of Fitness in Acute Myeloid Leukemia
por: Palmieri, Raffaele, et al.
Publicado: (2022)

Clinical value of new drugs in acute myeloid leukemia
por: Ossenkoppele, Gert
Publicado: (2019)

Chemotherapeutic Resistance in Egyptian Acute Myeloid Leukemia Patients
por: Kassem, Neemat M, et al.
Publicado: (2019)

Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia
por: Saliba, Antoine N., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_03kl8fqlo0blrrp4rrae5rjpoa